META vs. BMY
META (Meta Platforms, Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. META operates in Internet Content & Information (Communication Services), while BMY operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, META returned 17.64%/yr vs 0.92%/yr for BMY. At a 0.16 correlation, their price movements are largely independent.
Performance
META vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, META achieves a -10.09% return, which is significantly lower than BMY's 8.54% return. Over the past 10 years, META has outperformed BMY with an annualized return of 17.64%, while BMY has yielded a comparatively lower 0.92% annualized return.
META
- 1D
- -5.51%
- 1M
- -3.24%
- YTD
- -10.09%
- 6M
- -11.79%
- 1Y
- -13.11%
- 3Y*
- 30.15%
- 5Y*
- 12.59%
- 10Y*
- 17.64%
BMY
- 1D
- 1.18%
- 1M
- 1.20%
- YTD
- 8.54%
- 6M
- 12.26%
- 1Y
- 25.69%
- 3Y*
- 0.16%
- 5Y*
- 1.52%
- 10Y*
- 0.92%
META vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
META Meta Platforms, Inc. | -10.09% | 13.09% | 66.05% | 194.13% | -64.22% | 23.13% | 33.09% | 56.57% | -25.71% | 53.38% |
BMY Bristol-Myers Squibb Company | 8.54% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Correlation
The correlation between META and BMY is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.02 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.03 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.05 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since May 21, 2012 | 0.16 |
The correlation between META and BMY shifts across timeframes, from -0.03 (3 years) to 0.16 (all time), reflecting how their relationship changes across market environments.
Fundamentals
META:
$1.52T
BMY:
$117.03B
META:
$27.47
BMY:
$3.57
META:
21.59
BMY:
16.06
META:
0.89
BMY:
0.92
META:
7.09
BMY:
2.41
META:
6.24
BMY:
5.83
META:
$214.96B
BMY:
$48.48B
META:
$176.14B
BMY:
$33.33B
META:
$106.31B
BMY:
$13.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
META vs. BMY — Risk / Return Rank
META
BMY
META vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Meta Platforms, Inc. (META) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| META | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.33 | ||
| Sortino ratioReturn per unit of downside risk | -1.87 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.18 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | -0.40 | 1.89 | -2.28 |
| Martin ratioReturn relative to average drawdown | -0.84 | 4.15 | -4.99 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| META | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.37 | 0.96 | -1.33 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.29 | 0.06 | +0.22 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.46 | 0.04 | +0.42 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.55 | 0.35 | +0.20 |
Drawdowns
META vs. BMY - Drawdown Comparison
The maximum META drawdown since its inception was -76.74%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for META and BMY.
Loading charts...
Drawdown Indicators
| META | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -76.74% | -72.03% | -4.71% |
Max Drawdown (1Y)Largest decline over 1 year | -33.30% | -13.68% | -19.62% |
Max Drawdown (3Y)Largest decline over 3 years | -34.15% | -36.85% | +2.70% |
Max Drawdown (5Y)Largest decline over 5 years | -76.74% | -47.67% | -29.07% |
Max Drawdown (10Y)Largest decline over 10 years | -76.74% | -47.67% | -29.07% |
Current DrawdownCurrent decline from peak | -24.76% | -17.59% | -7.17% |
Average DrawdownAverage peak-to-trough decline | -15.26% | -22.38% | +7.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.60% | 6.21% | +9.39% |
Volatility
META vs. BMY - Volatility Comparison
Meta Platforms, Inc. (META) has a higher volatility of 10.46% compared to Bristol-Myers Squibb Company (BMY) at 7.08%. This indicates that META's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| META | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.46% | 7.08% | +3.38% |
Volatility (6M)Calculated over the trailing 6-month period | 27.14% | 17.90% | +9.24% |
Volatility (1Y)Calculated over the trailing 1-year period | 35.52% | 26.83% | +8.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 44.04% | 24.02% | +20.02% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 38.68% | 25.25% | +13.43% |
Dividends
META vs. BMY - Dividend Comparison
META's dividend yield for the trailing twelve months is around 0.35%, less than BMY's 4.37% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.37% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
META Meta Platforms, Inc. | 0.35% | 0.32% | 0.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
META vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Meta Platforms, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
META vs. BMY - Profitability Comparison
META - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported a gross profit of 46.09B and revenue of 56.31B. Therefore, the gross margin over that period was 81.9%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
META - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported an operating income of 22.87B and revenue of 56.31B, resulting in an operating margin of 40.6%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
META - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported a net income of 26.77B and revenue of 56.31B, resulting in a net margin of 47.5%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
Frequently Asked Questions
META and BMY have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
META has higher volatility (10.46%) compared to BMY (7.08%). In terms of maximum drawdown, META dropped -76.74% vs BMY's -72.03%.
BMY currently has the higher Sharpe Ratio (0.96 vs -0.37), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for META and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer